Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 17% of the time (192 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2009-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellfailureactiveagentdl
  Phrases that lowered it: participantssafetyevaluate theto evaluateopen label
• Sponsor's past termination rate: 16.7% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Drug's FAERS reports with a death: 16.2% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Blinding: none (raises risk) · Design
• Sponsor's past trials: 6 (lowers risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Keywords listed: 17 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa. NCT00752609 · started 2008 · scored riskier than 88% of active trials completed
• Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin. NCT00752791 · started 2008 · scored riskier than 80% of active trials completed
• Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease NCT04036253 · started 2018 · scored riskier than 67% of active trials completed
• Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis NCT01147666 · started 2010 · scored riskier than 26% of active trials completed
• Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment NCT01414075 · started 2011 · scored riskier than 62% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.